Login to Your Account



Morphosys Signs $818M Celgene Deal for MOR202

By Cormac Sheridan
Staff Writer

Friday, June 28, 2013
Shares in Morphosys AG surged by more than 17 percent during trading Thursday morning on news of a deal with Celgene Corp. for its anti-CD38 multiple myeloma antibody MOR202, worth an immediate €127 million (US$165.5 million) and which could be worth up to €628 million in total.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription